Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbon-13 MRI for Heart and Brain Metabolism in Type 2 Diabetes
NCT07820722Phase 1Not yet recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Oct 2026
- Primary completion
- Aug 2029
01
Overview
Phase 1, open-label trial of hyperpolarized 13C-pyruvate in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Sunnybrook Health Sciences Centre. Primary endpoints: Change in 13C-pyruvate at 4 months, Change in 13C-lactate at 4 months and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
hyperpolarized 13C-pyruvate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07820722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07820722.